Introduction: Adiponectin is secreted by adipocytes and has been linked to glucose and lipid regulation. Obesity, diabetes and atherosclerosis have been associated with reduced adiponectin levels. Orlistat lowers lipids and improves insulin sensitivity but its effect on other metabolic parameters is not known.
The purpose of this study is to evaluate the influence of orlistat on metabolic and hormonal parameters of the adipose tissue.
Materials and methods: Thirty obese female patients with Body Mass Index >30 kg/m2 and mean aged 48.7±12.9yrs and mean weight 92.47±12.5 kg were included. Patients with diabetes and thyroid disorders were excluded. All patients were on a low calorie diet one month before treatment with orlistat.Blood samples for glucose, total cholesterol triglycerides, HDL,LDL,FT4, TSH, insulin and adiponectin were obtained before and three months after orlistat treatment.
Results: 19/30 female (63.3%) have lost over five kilos after three months of treatment and diet. Mean body weight was 92.47±12.5 kg and 85.45±11.2 kg p<0.05 after treatment. Statistical signigicant differences between glycose triglycerides, cholesterol HDL,LDL were observed after treatment with orlistat(101±31.2 vs 85±14.5 mg/dl P<0.05, 207.5±29.8 vs 196.1±25.5 mg/dl P<0.004, 127.5±50.9 vs 119.2±41.4 mg/dl P<0.001).Insulin levels decreased significantly after three months of treatment (11.3±2.4 μU/ml vs 9.19±2.7 μU/ml P<0.00).In contrast adiponectin levels seemed to be increased significantly after treatment with orlistat.(16.284.5±21.640.6 vs 41.798.5±64.776.1 P<0.00)
Conclusion: In this study it seems that orlistat could effectively manage obesity. It decreases insulin and increases adiponectin when obese patients reduced caloric intake and lost weight after three months of treatment.